Neurocrine Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Neurocrine Biosciences has a total shareholder equity of $2.2B and total debt of $170.1M, which brings its debt-to-equity ratio to 7.6%. Its total assets and total liabilities are $3.3B and $1.0B respectively. Neurocrine Biosciences's EBIT is $394.8M making its interest coverage ratio -7.5. It has cash and short-term investments of $1.0B.
Key information
7.6%
Debt to equity ratio
US$170.10m
Debt
Interest coverage ratio | -7.5x |
Cash | US$1.03b |
Equity | US$2.23b |
Total liabilities | US$1.02b |
Total assets | US$3.25b |
Recent financial health updates
Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt
Dec 11Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Sep 12We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease
Jun 08Neurocrine Biosciences (NASDAQ:NBIX) Has A Rock Solid Balance Sheet
Mar 08Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Dec 08Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Quite Sensibly
Jul 26Recent updates
Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
Feb 11Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings
Jan 07Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt
Dec 11Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Sep 12We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease
Jun 08Neurocrine Biosciences (NASDAQ:NBIX) Has A Rock Solid Balance Sheet
Mar 08Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Dec 08Neurocrine initiated Equal Weight at Wells Fargo despite upcoming catalysts
Sep 26Neurocrine to acquire U.K.-based biotech Diurnal
Aug 30Sosei to get $30M from Neurocrine as schizophrenia drug gets FDA nod to enter phase 2 trial
Aug 05Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Quite Sensibly
Jul 26Better Ingrezza Sales And A Clinical Trial Read-Out Could Reignite Neurocrine Shares
Jul 19Is Neurocrine Biosciences (NASDAQ:NBIX) A Risky Investment?
Apr 11Financial Position Analysis
Short Term Liabilities: NBIX's short term assets ($1.6B) exceed its short term liabilities ($654.8M).
Long Term Liabilities: NBIX's short term assets ($1.6B) exceed its long term liabilities ($364.6M).
Debt to Equity History and Analysis
Debt Level: NBIX has more cash than its total debt.
Reducing Debt: NBIX's debt to equity ratio has reduced from 80.8% to 7.6% over the past 5 years.
Debt Coverage: NBIX's debt is well covered by operating cash flow (229.2%).
Interest Coverage: NBIX earns more interest than it pays, so coverage of interest payments is not a concern.